Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
LENZ Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
LENZ Stock 12 Month Forecast
Average Price Target
$49.50
▲(23.75% Upside)
| Highest Price Target$60.00 | Average Price Target$49.50 | Lowest Price Target$36.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
$60
Buy
50.00%
Upside
Reiterated
08/22/25
H.C. Wainwright
$48→$56
Buy
40.00%
Upside
Reiterated
08/22/25
Leerink Partners
$36
Buy
-10.00%
Downside
Reiterated
08/01/25
Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye DropsWe also believe the inclusion of the data demonstrating the durability of the effect for 10 hours will help to differentiate the product from the other presbyopia eye drops. The company has activated its branded commercial launch plan with its 88-member sales force and is planning to distribute samples to targeted optometrist offices no later than October. We also like the discount offered by the company on a 3-month supply (~16% discount/unit), as it should drive adoption of this product. Importantly, the company has $205M in cash, which includes recent upfront payments from the licensing agreements in Canada, so it’s well funded for launch.
Bank of America Securities
$44→$53
Buy
32.50%
Upside
Reiterated
08/01/25
Citi
$49→$52
Buy
30.00%
Upside
Assigned
07/31/25
Raymond James
$39→$40
Buy
0.00%
Upside
Reiterated
07/31/25
William Blair
―
Buy
―
Reiterated
07/30/25
LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval1:44 PM Research | Healthcare LENZ Therapeutics, Inc. (LENZ) $31.67 Market Value (M): $891 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- 8 PDUFA What’s new? The FDA’s review of the LNZ100 NDA continues to progress with no delays or interruptions to date. The company completed its late-cycle review in May, and the FDA has noted no significant review issues. Lenz also continued to advance its commercial preparations during the second quarter, and has now completed hiring of its 88-member salesforce that is prepared to initiate sales-and-marketing activities immediately upon U.S. approval.
Piper Sandler
$51
Buy
27.50%
Upside
Reiterated
05/08/25
TR | OpenAI - 4o
―
Hold
―
Upgraded
04/20/25
Unknown Analyst
TD SecuritiesNot Ranked
TD Securities
$60
Buy
50.00%
Upside
Initiated
03/18/25
Initiating At Buy: Ideal Eye Drop For Aging Eyes, In A Large Presbyopia Market We are initiating LENZ with a $60 target.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
$60
Buy
50.00%
Upside
Reiterated
08/22/25
H.C. Wainwright
$48→$56
Buy
40.00%
Upside
Reiterated
08/22/25
Leerink Partners
$36
Buy
-10.00%
Downside
Reiterated
08/01/25
Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye DropsWe also believe the inclusion of the data demonstrating the durability of the effect for 10 hours will help to differentiate the product from the other presbyopia eye drops. The company has activated its branded commercial launch plan with its 88-member sales force and is planning to distribute samples to targeted optometrist offices no later than October. We also like the discount offered by the company on a 3-month supply (~16% discount/unit), as it should drive adoption of this product. Importantly, the company has $205M in cash, which includes recent upfront payments from the licensing agreements in Canada, so it’s well funded for launch.
Bank of America Securities
$44→$53
Buy
32.50%
Upside
Reiterated
08/01/25
Citi
$49→$52
Buy
30.00%
Upside
Assigned
07/31/25
Raymond James
$39→$40
Buy
0.00%
Upside
Reiterated
07/31/25
William Blair
―
Buy
―
Reiterated
07/30/25
LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval1:44 PM Research | Healthcare LENZ Therapeutics, Inc. (LENZ) $31.67 Market Value (M): $891 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- 8 PDUFA What’s new? The FDA’s review of the LNZ100 NDA continues to progress with no delays or interruptions to date. The company completed its late-cycle review in May, and the FDA has noted no significant review issues. Lenz also continued to advance its commercial preparations during the second quarter, and has now completed hiring of its 88-member salesforce that is prepared to initiate sales-and-marketing activities immediately upon U.S. approval.
Piper Sandler
$51
Buy
27.50%
Upside
Reiterated
05/08/25
TR | OpenAI - 4o
―
Hold
―
Upgraded
04/20/25
Unknown Analyst
TD SecuritiesNot Ranked
TD Securities
$60
Buy
50.00%
Upside
Initiated
03/18/25
Initiating At Buy: Ideal Eye Drop For Aging Eyes, In A Large Presbyopia Market We are initiating LENZ with a $60 target.
Best Analysts Covering LENZ Therapeutics
1 Month
xxx
Success Rate
5/7 ratings generated profit
Average Return
+11.97%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +11.97% per trade.
3 Months
xxx
Success Rate
6/7 ratings generated profit
Average Return
+27.10%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +27.10% per trade.
1 Year
2 Years
xxx
Success Rate
11/11 ratings generated profit
Average Return
+59.26%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +59.26% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LENZ Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
9
11
9
7
8
Buy
7
10
6
9
8
Hold
2
2
1
0
0
Sell
2
2
2
0
0
Strong Sell
0
0
0
0
0
total
20
25
18
16
16
Each month's total comprises the sum of three months' worth of ratings.
LENZ Financial Forecast
LENZ Stock Forecast FAQ
What is LENZ’s average 12-month price target, according to analysts?
Based on analyst ratings, LENZ Therapeutics’s 12-month average price target is 49.50.
What is LENZ’s upside potential, based on the analysts’ average price target?
LENZ Therapeutics has 23.75% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LENZ a Buy, Sell or Hold?
LENZ Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is LENZ Therapeutics’s price target?
The average price target for LENZ Therapeutics is 49.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $36.00. The average price target represents 23.75% Increase from the current price of $40.
The highest analyst price target is $60.00 ,the lowest forecast is $36.00. The average price target represents 23.75% Increase from the current price of $40.
What do analysts say about LENZ Therapeutics?
LENZ Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of LENZ?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.